Display options
Cite
Deng B, Jia LQ, Tan HY, et al. Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis. Evid Based Complement Alternat Med. 2012;2012:381904doi: 10.1155/2012/381904.
Deng, B., Jia, L. Q., Tan, H. Y., Yao, X., Gao, F. Y., Pan, L., Cui, J., & Xiang, Q. (2012). Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis. Evidence-based complementary and alternative medicine : eCAM, 2012381904. https://doi.org/10.1155/2012/381904
Deng, Bo, et al. "Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis." Evidence-based complementary and alternative medicine : eCAM vol. 2012 (2012): 381904. doi: https://doi.org/10.1155/2012/381904
Deng B, Jia LQ, Tan HY, Yao X, Gao FY, Pan L, Cui J, Xiang Q. Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis. Evid Based Complement Alternat Med. 2012;2012:381904. doi: 10.1155/2012/381904. Epub 2012 Nov 06. PMID: 23243441; PMCID: PMC3514842.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2012;2012:381904. doi: 10.1155/2012/381904. Epub 2012 Nov 06.

Effects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasis.

Evidence-based complementary and alternative medicine : eCAM

Bo Deng, Li-Qun Jia, Huang-Ying Tan, Xuan Yao, Fu-Yun Gao, Lin Pan, Jian Cui, Qing Xiang

Affiliations

  1. Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing 100029, China ; School of Clinical Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.

PMID: 23243441 PMCID: PMC3514842 DOI: 10.1155/2012/381904

Abstract

Bone metastasis (BM) is a major clinical problem for which current treatments lack full efficacy. The Traditional Chinese Medicine (TCM) Sangu Decoction (SGD) has been widely used to treat BM in China. However, no in vivo experiments to date have investigated the effects of TCM on osteoclast activity in BM. In this study, the protective effect and probable mechanism of SGD were evaluated. The model was established using the breast cancer MRMT-1 cells injected into the tibia of rat. SGD was administrated, compared with Zoledronic acid as a positive control. The development of the bone tumor and osteoclast activity was monitored by radiological analysis. TRAP stain was used to identify osteoclasts quantity and activity. TRAP-5b in serum or bone tumor and TRAP mRNA were also quantified. Radiological examination showed that SGD inhibited tumor proliferation and preserved the cortical and trabecular bone structure. In addition, a dramatic reduction of TRAP positive osteoclasts was observed and TRAP-5b levels in serum and bone tumor decreased significantly. It also reduced the mRNA expression of TRAP. The results indicated that SGD exerted potent antiosteoclast property that could be directly related to its TRAP inhibited activity. In addition it prevented bone tumor proliferation in BM model.

References

  1. Life Sci. 2006 Oct 19;79(21):2043-8 - PubMed
  2. Cancer Treat Rev. 2008 Nov;34(7):629-39 - PubMed
  3. Pain. 2002 Dec;100(3):219-229 - PubMed
  4. Clin Exp Metastasis. 2006;23(3-4):167-75 - PubMed
  5. Clin Oncol (R Coll Radiol). 2011 Aug;23(6):387-92 - PubMed
  6. Cancer Lett. 2009 Sep 28;283(1):10-9 - PubMed
  7. Endocr Relat Cancer. 2000 Dec;7(4):271-84 - PubMed
  8. J Theor Biol. 2010 Jan 21;262(2):306-16 - PubMed
  9. Bioorg Med Chem Lett. 2012 Aug 1;22(15):5008-12 - PubMed
  10. Methods. 2001 Dec;25(4):402-8 - PubMed
  11. Cancer. 1997 Oct 15;80(8 Suppl):1546-56 - PubMed
  12. Phytomedicine. 2011 Mar 15;18(5):425-30 - PubMed
  13. Oncology. 2006;71(5-6):374-81 - PubMed
  14. Acta Histochem. 2011 Feb;113(2):73-81 - PubMed
  15. Oncology. 1984;41(4):245-51 - PubMed
  16. Bone. 2010 Oct;47(4):795-803 - PubMed
  17. J Oral Maxillofac Surg. 2006 May;64(5):828-37 - PubMed
  18. Pain. 2002 Mar;96(1-2):129-40 - PubMed
  19. Eur J Pharmacol. 2007 Jan 26;555(2-3):218-25 - PubMed
  20. Biochem Biophys Res Commun. 2011 Feb 11;405(2):256-61 - PubMed
  21. Eur J Med Chem. 2006 Mar;41(3):367-72 - PubMed
  22. Cancer Res. 2006 Feb 15;66(4):2067-73 - PubMed
  23. Bull Cancer. 2006 Sep;93(9):931-43 - PubMed
  24. J Ethnopharmacol. 2012 Jan 6;139(1):311-7 - PubMed
  25. J Ethnopharmacol. 2005 Jan 15;96(3):489-95 - PubMed
  26. Nat Rev Cancer. 2002 Aug;2(8):584-93 - PubMed
  27. Chin J Integr Med. 2012 Apr;18(4):304-7 - PubMed
  28. Vascul Pharmacol. 2011 Jan-Feb;54(1-2):18-28 - PubMed
  29. J Ethnopharmacol. 2010 Nov 11;132(2):456-60 - PubMed
  30. Cancer Epidemiol. 2012 Feb;36(1):94-8 - PubMed
  31. Int Immunopharmacol. 2003 Nov;3(12):1685-97 - PubMed

Publication Types